NLS Agreement

The two companies have partnered to offer an integrated development and manufacturing pathway for recombinant protein programs in E. coli.

The agreement for distribution and commercialization of Pepaxti in Central and Eastern Europe addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states.

Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient, the company states.

Genovis has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ EndoS2 enzyme technology for the research, development, manufacture, and commercialization of antibody-drug conjugate (ADC) therapeutics.

Mendus has entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), an Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in acute myeloid leukemia (AML).